ISRCTN65524939 https://doi.org/10.1186/ISRCTN65524939

A randomised, double-blind, efficacy and dose finding study of intermittent preventive treatment with dihydroartemisinin-piperaquine for prevention of malaria

Submission date
06/08/2006

Registration date
08/08/2006

Last Edited
20/03/2013

Recruitment status
No longer recruiting

Overall study status
Completed

Condition category
Infections and Infestations

[X] Prospectively registered
[_] Protocol
[_] Statistical analysis plan
[X] Results
[_] Individual participant data

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Francois Nosten

Contact details
Shoklo Malaria Research Unit
68/30 Baan Tung Road
Mae Sot
Thailand
63110
+66 (0)55 545 021
SMRU@tropmedres.ac

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
041843

Study information

Scientific Title

Acronym
DCIPT

Study objectives
The combination of dihydroartemisinin and piperaquine is effective in the prevention of Plasmodium falciparum malaria.

Ethics approval required
Old ethics approval format

Ethics approval(s)
Oxford Tropical Ethics Research Committee approval gained (reference number: 028-05).

Study design
Double blind, placebo controlled trial

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied
Plasmodium falciparum malaria

Interventions
Intermittent Preventive Treatment (IPT) of dihydroartemisinin and piperaquine versus a placebo.

Intervention Type
Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)
Dihydroartemisinin and piperaquine

Primary outcome measure
Incidence of malaria

Secondary outcome measures
Safety

Overall study start date
15/08/2006

Completion date
31/12/2007

Eligibility

Key inclusion criteria
1. Male
2. Aged over 18 years
3. Willingness to attend for follow up for nine months
4. Written informed consent given to participate in the trial

Participant type(s)
Patient

Age group
Adult

Lower age limit
18 Years

Sex
Male

Target number of participants
780

Key exclusion criteria
1. Malaria asexual stage parasitaemia
2. Dapsone Pyrimethamine (DP) treatment within the past six months
3. Mefloquine treatment within the past two months
4. Known hypersensitivity to artemisinins or DP

Date of first enrolment
15/08/2006

Date of final enrolment

31/12/2007

Locations

Countries of recruitment
Thailand

Study participating centre
Shoklo Malaria Research Unit
Mae Sot
Thailand
63110

Sponsor information

Organisation
University of Oxford (UK)

Sponsor details
Centre for Clinical Vaccinology and Tropical Medicine
Churchill Hospital
Old Road
Oxford
England
United Kingdom
OX3 7LJ
+44 (0)1865 857433
paul.hogben@ndm.ox.ac.uk

Sponsor type
University/education

Website
http://www.ccvtm.ox.ac.uk/

ROR
https://ror.org/052gg0110

Funder(s)

Funder type
Charity

Funder Name
The Wellcome Trust (UK) (grant ref: 041843)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary
Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/03/2012		Yes	No